Ribavirin enhances osteoclast formation through osteoblasts via up-regulation of TRANCE/RANKL

Molecular and Cellular Biochemistry

Volumn 296, Issue 1-2, 2007, Pages 17-24

  Lee, Junwon ^a   Kim, Jung Ha ^a   Kim, Kabsun ^a   Jin, Hey Mi ^a   Lee, Keun Bae ^a   Chung, Dong Jin ^a   Kim, Nacksung ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Hepatitis C; Osteoclastogenesis; Ribavirin; TRANCE RANKL

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; ANTIVIRUS AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; RIBAVIRIN; TNFSF11 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS C; HUMAN; METABOLISM; MOUSE; OSTEOBLAST; OSTEOCLAST; PHYSIOLOGY;

ALKALINE PHOSPHATASE; ANIMALS; ANTIVIRAL AGENTS; CELL DIFFERENTIATION; CELL LINE; GENE EXPRESSION REGULATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND; RIBAVIRIN;

EID: 34347205363     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-006-9293-5     Document Type: Article

References (19)

1. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315: 1575-1578, 1986
2. McHutchison JG, Poynard T: Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 19 Suppl(1): 57-65, 1999
3. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343: 1666-1672, 2000
4. Tsuneoka K, Tameda Y, Takase K, Nakano T: Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol 31: 669-678, 1996
5. Crosbie OM, Freaney R, McKenna MJ, Hegarty JE: Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease. Calcif Tissue Int 64: 295-300, 1999
6. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D: Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 28: 695-699, 1998
7. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, Moreno- Otero R, Alonso JL, Yague E, Pivel JP, Lopez-Cabrera M, Fernandez-Ruiz E, Sanchez-Madrid F: Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 179: 841-848, 1994
8. Van der Merwe SW, van den Bogaerde JB, Goosen C, Maree FF, Milner RJ, Schnitzler CM, Biscardi A, Mesquita JM, Engelbrecht G, Kahn D, Fevery J: Hepatic osteodystrophy in rats results mainly from portasystemic shunting. Gut 52: 580-585, 2003
9. Coelho LF, de Freitas Almeida GM, Mennechet FJ, Blangy A, Uze G: Interferon-{alpha} and -{beta} differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci USA 102: 11917-11922, 2005
10. Weide R, Ehlenz K, Lorenz W, Walthers E, Klausmann M, Pfluger KH: Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 72: 41-43, 1996
11. Solis-Herruzo JA, Castellano G, Fernandez I, Munoz R, Hawkins F: Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 33: 812-817, 2000
12. Trombetti A, Giostra E, Mentha G, Negro F, Rizzoli R: Lack of evidence for ribavirin-induced bone loss. Hepatology 36: 255-257, 2002
13. Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, Kook H, Kim KK, Choi Y, Kim N: Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 280: 35209-35216, 2005
14. So H, Rho J, Jeong D, Park R, Fisher DE, Ostrowski MC, Choi Y, Kim N: Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression. J Biol Chem 278: 24209-24216, 2003
15. Suda T, Jimi E, Nakamura I, Takahashi N: Role of 1 alpha,25- dihydroxyvitamin D3 in osteoclast differentiation, function. Methods Enzymol 282: 223-235, 1997
16. Moreira RO, Balduino A, Martins HS, Reis JS, Duarte ME, Farias ML, Borojevic R: Ribavirin, but not interferon alpha-2b, is associated with impaired osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 75: 160-168, 2004
17. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540-3545, 1999
18. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357, 1999
19. Glue P: The clinical pharmacology of ribavirin. Semin Liver Dis 19(Suppl 1): 17-24, 1999